| Abstrakt: |
A recent study conducted at the Netherlands Cancer Institute focused on understanding the impact of the CHEK2 c.1100delC variant on cancer risk and prognosis, particularly in breast cancer cases. The study included 1802 women, with findings indicating that carriers of the variant were diagnosed with breast cancer at a younger age and were more likely to develop contralateral breast cancer. Future plans involve further data linkages to assess breast cancer risk, survival rates, and tumorigenesis. This research provides valuable insights into genetic factors influencing cancer risk and treatment outcomes. [Extracted from the article] |
